FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380793721> ?p ?o ?g. }

• W4380793721 abstract "Introduction: PH is a disorder characterized by remodeling of the pulmonary vasculature which causes increased pulmonary vascular resistance and ultimately right ventricular (RV) failure leading to death. MetS is a recognized risk factor for PH, particularly in patients suffering from PH associated with left-sided heart failure (WHO Group 2 PH) for which there are no approved therapies. Activins and growth differentiation factors (GDFs) are implicated in both PH pathology as well as body composition and metabolism by genetic disease association, preclinical, translational, and clinical evidence. HS135 is a rationally designed first-in-class activin-receptor (ActR)-based fusion protein that addresses both vascular remodeling and MetS in PH without affecting hematological parameters; hematological effects limit the dosing of other ActR-based agents. Methods: HS135’s ability to counteract vascular remodeling and heart failure in PH was assessed using a rat monocrotaline (MCT) model: a single dose of 60 mg/kg MCT was administered on Day 0 followed by 4 weeks of twice weekly treatment with either HS135 (1, 4, or 16 mg/kg) or vehicle. PH efficacy was assessed at end of study by echocardiography and histological readouts. HS135’s ability to improve body composition and metabolism was assessed in wild type mice by administering HS135 (1, 3, 10, 20, or 50 mg/kg) or vehicle twice weekly for 3 weeks. The effect of HS135 on hematological parameters was assessed by whole blood cell count in non-human primates (NHPs) 2 weeks following a single administration of HS135 at 3 or 30 mg/kg. Results: HS135 at 3 or 30 mg/kg did not lead to changes in hematological parameters in NHPs. Compared to vehicle, HS135 was effective at counteracting the MCT-induced PH phenotype in rats as evidenced by significant reductions in Fulton index and improved echocardiography parameters. In wild type mice, HS135 led to significant improvements in body composition. Conclusions: Contrary to other ActR-based therapies, HS135 did not lead to increases in hematocrit which would limit its dosing. HS135 was efficacious at treating PH while simultaneously improving body composition in preclinical models. Clinical trials with HS135 are expected to commence within 2023." @default.
• W4380793721 created "2023-06-16" @default.
• W4380793721 creator A5016404458 @default.
• W4380793721 creator A5023536473 @default.
• W4380793721 creator A5036584692 @default.
• W4380793721 creator A5037955697 @default.
• W4380793721 creator A5058644101 @default.
• W4380793721 creator A5061652560 @default.
• W4380793721 creator A5066827889 @default.
• W4380793721 creator A5075549153 @default.
• W4380793721 date "2022-11-08" @default.
• W4380793721 modified "2023-10-18" @default.
• W4380793721 title "Abstract 10487: In vivo Efficacy of HS135, a Novel Activin and GDF Trap for the Treatment of Pulmonary Hypertension (PH) and Metabolic Syndrome (MetS)" @default.
• W4380793721 doi "https://doi.org/10.1161/circ.146.suppl_1.10487" @default.
• W4380793721 hasPublicationYear "2022" @default.
• W4380793721 type Work @default.
• W4380793721 citedByCount "0" @default.
• W4380793721 crossrefType "journal-article" @default.
• W4380793721 hasAuthorship W4380793721A5016404458 @default.
• W4380793721 hasAuthorship W4380793721A5023536473 @default.
• W4380793721 hasAuthorship W4380793721A5036584692 @default.
• W4380793721 hasAuthorship W4380793721A5037955697 @default.
• W4380793721 hasAuthorship W4380793721A5058644101 @default.
• W4380793721 hasAuthorship W4380793721A5061652560 @default.
• W4380793721 hasAuthorship W4380793721A5066827889 @default.
• W4380793721 hasAuthorship W4380793721A5075549153 @default.
• W4380793721 hasConcept C126322002 @default.
• W4380793721 hasConcept C136935669 @default.
• W4380793721 hasConcept C164705383 @default.
• W4380793721 hasConcept C178853913 @default.
• W4380793721 hasConcept C2778198053 @default.
• W4380793721 hasConcept C2780930700 @default.
• W4380793721 hasConcept C58245268 @default.
• W4380793721 hasConcept C71924100 @default.
• W4380793721 hasConcept C90924648 @default.
• W4380793721 hasConceptScore W4380793721C126322002 @default.
• W4380793721 hasConceptScore W4380793721C136935669 @default.
• W4380793721 hasConceptScore W4380793721C164705383 @default.
• W4380793721 hasConceptScore W4380793721C178853913 @default.
• W4380793721 hasConceptScore W4380793721C2778198053 @default.
• W4380793721 hasConceptScore W4380793721C2780930700 @default.
• W4380793721 hasConceptScore W4380793721C58245268 @default.
• W4380793721 hasConceptScore W4380793721C71924100 @default.
• W4380793721 hasConceptScore W4380793721C90924648 @default.
• W4380793721 hasIssue "Suppl_1" @default.
• W4380793721 hasLocation W43807937211 @default.
• W4380793721 hasOpenAccess W4380793721 @default.
• W4380793721 hasPrimaryLocation W43807937211 @default.
• W4380793721 hasRelatedWork W1984386442 @default.
• W4380793721 hasRelatedWork W1988218045 @default.
• W4380793721 hasRelatedWork W2012294231 @default.
• W4380793721 hasRelatedWork W2090835731 @default.
• W4380793721 hasRelatedWork W2125804349 @default.
• W4380793721 hasRelatedWork W2597831352 @default.
• W4380793721 hasRelatedWork W2888088163 @default.
• W4380793721 hasRelatedWork W2905087291 @default.
• W4380793721 hasRelatedWork W4251612387 @default.
• W4380793721 hasRelatedWork W4377823078 @default.
• W4380793721 hasVolume "146" @default.
• W4380793721 isParatext "false" @default.
• W4380793721 isRetracted "false" @default.
• W4380793721 workType "article" @default.